

Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients

Antonio Silvani · Elena Lamperti · Paola Gaviani · Marica Eoli ·
Anna Fiumani · Andrea Salmaggi · Chiara Falcone · Graziella Filippini ·
Andrea Botturi · Amerigo Boiardi

Published online: 8 February 2008
© Springer Science+Business Media, LLC. 2008

Erratum to: J Neurooncol DOI 10.1007/s11060-007-9427-y

There were errors in Table 2 of the original publication. The corrected values are shown in bold in Table 2 below. The corresponding values in the text of the original publication were correct (2nd and 3rd paragraph of left column on the same page).

Table 2 Overall Median PFS and 6 months-PFS from the start of PCB–FTM

	Median PFS: weeks (95% CI)	PFS-6: % (95% CI)
Whole group of 54 recurrent glioblastoma patients	19.3 (13.7–24.4)	26.7 (10.6–42.8)
II line chemotherapy: 31 patients treated at first recurrence-progression	19.7 (13.7–25.2)	17.1 (0–34.3)
Reoperated	19.7 (13.6–26.1)	ne
Non-reoperated	16.7 (6.8–26.5)	42.8 (8.8–77)
III line chemotherapy: 23 patients treated at second recurrence-progression	19.3 (6.8 –32.1)	45.8 (16.6–75)
Reoperated	25.7 (13.3–38.6)	50.9 (19.1–82.7)
Non-reoperated	ne	ne

ne = 100% of progression or censored before 6 months

The online version of the original article can be found under doi:[10.1007/s11060-007-9427-y](https://doi.org/10.1007/s11060-007-9427-y).

A. Silvani (✉) · E. Lamperti · P. Gaviani · M. Eoli ·
A. Fiumani · A. Salmaggi · A. Botturi · A. Boiardi
Department of Neuro-oncology, Fondazione IRCCS Istituto
Neurologico “Carlo Besta”, Via Celoria, 11, Milan 20133, Italy
e-mail: silvani@istituto-besta.it

C. Falcone · G. Filippini
Neuro-epidemiology Unit, Fondazione IRCCS Istituto
Neurologico “Carlo Besta”, Via Celoria, 11, Milan 20133, Italy